Digital Content 
NEWS #PharmaBuzz
18 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biomarin-to-present-data-underscoring-sustained-positive-impact-of-voxzogo-vosoritide-on-health-related-quality-of-life-growth-and-maintenance-of-bone-strength-in-children-with-achondroplasia-at-2024-international-skeletal-dys-302251087.html
17 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biomarin-to-present-data-highlighting-significant-impact-of-voxzogo-vosoritide-in-bone-health-and-health-related-quality-of-life-in-achondroplasia-at-2024-international-conference-on-childrens-bone-health-302173608.html
https://investors.biomarin.com/news/news-details/2024/New-Data-for-BioMarins-VOXZOGO-vosoritide-for-Multiple-Growth-Related-Conditions-in-Children-Presented-at-Pediatric-Endocrine-Society-PES-Annual-Meeting/default.aspx
12 Mar 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/new-data-to-be-presented-for-biomarins-voxzogo-vosoritide-in-children-with-hypochondroplasia-and-achondroplasia-at-the-american-college-of-medical-genetics-and-genomics-acmg-annual-clinical-genetics-meeting-302085829.html
21 Oct 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-biomarins-voxzogo-vosoritide-for-children-under-5-years-with-achondroplasia-301963505.html
21 Sep 2023
// PRESS RELEASE
https://investors.biomarin.com/2023-09-21-BioMarin-to-Present-Data-Showing-Long-Term-Benefit-of-VOXZOGO-R-vosoritide-on-Growth-in-Children-with-Achondroplasia-at-2023-European-Society-for-Paediatric-Endocrinology-ESPE-Meeting
Share 